AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Rocket Companies, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Davidson Kempner affiliates disclose a near-maximum 9.9% passive stake in Biora Therapeutics (BIOR). On 30 Jun 2025 the hedge-fund complex � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and Managing Member Anthony A. Yoseloff � filed Amendment No. 1 to Schedule 13G.

  • Total beneficial ownership: up to 906,227 common shares (including 851,177 issuable on note conversion), representing 9.90 % of BIOR’s 4,552,702 outstanding shares.
  • Structure: All voting and dispositive power is shared; none of the entities have sole power.
  • Convertible notes: 91 % of the reported position is in notes convertible into equity, but conversions are capped by a 9.90 % blocker, limiting immediate dilution.
  • M.H. Davidson & Co. separately lists 25,624 shares (0.56 %) including 24,033 from notes.
  • The group certifies the position is passive (Rule 13d-1(c)) and not intended to influence control.

The disclosure signals a sizable institutional bet on BIOR while highlighting potential dilution from convertible securities, though the blocker tempers near-term ownership expansion.

Le affiliate di Davidson Kempner comunicano una partecipazione passiva quasi massima del 9,9% in Biora Therapeutics (BIOR). Il 30 giugno 2025 il gruppo hedge fund � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP e il membro gestore Anthony A. Yoseloff � ha presentato l'emendamento n. 1 al Schedule 13G.

  • Proprietà effettiva totale: fino a 906.227 azioni ordinarie (inclusi 851.177 azioni convertibili da note), pari al 9,90% delle 4.552.702 azioni in circolazione di BIOR.
  • Struttura: Tutti i poteri di voto e dispositivi sono condivisi; nessuna entità ha potere esclusivo.
  • Note convertibili: Il 91% della posizione dichiarata è rappresentato da note convertibili in azioni, ma le conversioni sono limitate da un blocco al 9,90%, riducendo la diluizione immediata.
  • M.H. Davidson & Co. segnala separatamente 25.624 azioni (0,56%), incluse 24.033 da note.
  • Il gruppo certifica che la posizione è passiva (Regola 13d-1(c)) e non ha l’intenzione di influenzare il controllo.

La comunicazione evidenzia una significativa scommessa istituzionale su BIOR, mettendo in luce la possibile diluizione derivante dalle azioni convertibili, anche se il blocco limita l’espansione della proprietà nel breve termine.

Las filiales de Davidson Kempner revelan una participación pasiva cercana al máximo del 9,9% en Biora Therapeutics (BIOR). El 30 de junio de 2025, el grupo de fondos de cobertura � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP y el miembro gerente Anthony A. Yoseloff � presentó la Enmienda N° 1 al Schedule 13G.

  • Propiedad beneficiosa total: hasta 906,227 acciones comunes (incluyendo 851,177 acciones emitibles por conversión de notas), que representan el 9,90% de las 4,552,702 acciones en circulación de BIOR.
  • Estructura: Todo el poder de voto y disposición es compartido; ninguna entidad tiene poder exclusivo.
  • Notas convertibles: El 91% de la posición reportada está en notas convertibles en acciones, pero las conversiones están limitadas por un tope del 9,90%, lo que restringe la dilución inmediata.
  • M.H. Davidson & Co. reporta por separado 25,624 acciones (0,56%), incluyendo 24,033 provenientes de notas.
  • El grupo certifica que la posición es pasiva (Regla 13d-1(c)) y no pretende influir en el control.

La divulgación señala una apuesta institucional considerable en BIOR, destacando la posible dilución por valores convertibles, aunque el tope modera la expansión de la propiedad a corto plazo.

ë°ì´ë¹„드ìŠ� ì¼í”„ë„� 계열사가 Biora Therapeutics(BIOR)ì—� 대í•� ê±°ì˜ ìµœëŒ€ì¹˜ì¸ 9.9%ì� ìˆ˜ë™ ì§€ë¶„ì„ ê³µì‹œí–ˆìŠµë‹ˆë‹¤. 2025ë…� 6ì›� 30ì�, 헤지펀ë“� 그룹ì� M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP ë°� 매니ì§� 멤버 Anthony A. Yoseloffê°€ Schedule 13G 수정ì•� 1호를 제출했습니다.

  • ì´� 실질 소유ê¶�: 최대 906,227ì£� 보통ì£�(노트 전환으로 발행 가능한 851,177ì£� í¬í•¨)ë¡� BIORì� ì´� 4,552,702ì£� ì¤� 9.90%ì—� 해당합니ë‹�.
  • 구조: 모든 ì˜ê²°ê¶� ë°� 처분 ê¶Œí•œì€ ê³µìœ ë˜ë©°, ì–´ëŠ ë²•ì¸ë� ë‹¨ë… ê¶Œí•œì� ê°–ê³  있지 않습니다.
  • 전환사채: ë³´ê³ ë� í¬ì§€ì…˜ì˜ 91%ê°€ 주ì‹ìœ¼ë¡œ 전환 가능한 노트ì—� 해당하지ë§�, ì „í™˜ì€ 9.90% 제한 장치ì—� ì˜í•´ 제한ë˜ì–´ 즉ê°ì ì¸ í¬ì„ 효과ë¥� 줄입니다.
  • M.H. Davidson & Co.ëŠ� 노트ì—서 24,033주를 í¬í•¨í•� 25,624ì£�(0.56%)ë¥� 별ë„ë¡� 보고합니ë‹�.
  • ê·¸ë£¹ì€ ì� í¬ì§€ì…˜ì´ 수ë™ì ìž„ì� 규칙 13d-1(c)ì—� ë”°ë¼ ì¸ì¦í•˜ë©°, 지배력 행사 ì˜ë„ê°€ ì—†ìŒì� 명확íž� 합니ë‹�.

ì´ë²ˆ 공시ëŠ� BIORì—� 대í•� ìƒë‹¹í•� 기관 íˆ¬ìž ë² íŒ…ì� 나타내며, 전환 ì¦ê¶Œìœ¼ë¡œ ì¸í•œ í¬ì„ 가능성ì� 강조하지ë§� 제한 장치가 단기ì ì¸ ì§€ë¶� 확대ë¥� 완화합니ë‹�.

Les filiales de Davidson Kempner révèlent une participation passive proche du maximum de 9,9 % dans Biora Therapeutics (BIOR). Le 30 juin 2025, le groupe de hedge funds � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP et le membre gérant Anthony A. Yoseloff � a déposé l’Amendement n° 1 au Schedule 13G.

  • Propriété bénéficiaire totale : jusqu’Ã� 906 227 actions ordinaires (dont 851 177 actions pouvant être émises par conversion de billets), représentant 9,90 % des 4 552 702 actions en circulation de BIOR.
  • Structure : Tous les pouvoirs de vote et de disposition sont ±è²¹°ù³Ù²¹²µÃ©²õ ; aucune entité ne détient de pouvoir exclusif.
  • Billets convertibles : 91 % de la position déclarée est constituée de billets convertibles en actions, mais les conversions sont limitées par un plafond de 9,90 %, ce qui limite la dilution immédiate.
  • M.H. Davidson & Co. déclare séparément 25 624 actions (0,56 %), dont 24 033 provenant de billets.
  • Le groupe certifie que la position est passive (Règle 13d-1(c)) et n’a pas l’intention d’influencer le contrôle.

Cette divulgation signale un pari institutionnel important sur BIOR tout en soulignant la dilution potentielle liée aux titres convertibles, bien que le plafond limite l’expansion de la participation à court terme.

Davidson Kempner-Tochtergesellschaften geben eine nahezu maximale passive Beteiligung von 9,9 % an Biora Therapeutics (BIOR) bekannt. Am 30. Juni 2025 reichte der Hedgefonds-Komplex � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP sowie Managing Member Anthony A. Yoseloff � Änderung Nr. 1 zum Schedule 13G ein.

  • Gesamtnutzungsrechte: Bis zu 906.227 Stammaktien (einschließlich 851.177 aus der Wandlung von Schuldscheinen), was 9,90 % der 4.552.702 ausstehenden BIOR-Aktien entspricht.
  • Struktur: Alle Stimm- und Verfügungsrechte werden geteilt; keine der Einheiten verfügt über Alleinrechte.
  • Wandelanleihen: 91 % der gemeldeten Position bestehen aus in Aktien wandelbaren Schuldscheinen, jedoch sind Wandlungen durch eine 9,90 %-Blockade begrenzt, wodurch eine sofortige Verwässerung eingeschränkt wird.
  • M.H. Davidson & Co. meldet separat 25.624 Aktien (0,56 %), davon 24.033 aus Wandelanleihen.
  • Die Gruppe bestätigt, dass die Position passiv ist (Regel 13d-1(c)) und nicht darauf abzielt, Kontrolle auszuüben.

Die Meldung signalisiert eine bedeutende institutionelle Wette auf BIOR und weist auf mögliche Verwässerungen durch wandelbare Wertpapiere hin, wobei die Blockade eine kurzfristige Ausweitung der Beteiligung begrenzt.

Positive
  • Institutional validation: A well-known hedge fund complex committing up to 9.9 % of BIOR may boost market confidence and liquidity.
Negative
  • Potential dilution: 851,177 shares are issuable from convertible notes, creating an overhang once the 9.9 % blocker constraint eases.

Insights

TL;DR � Hedge fund holds 9.9 % via notes, signalling confidence but creating convertible overhang.

Davidson Kempner’s 906 k-share exposure (almost entirely via convertibles) equals the legal ownership ceiling. For a micro-cap with <5 m shares outstanding, this stake is material, adding a sophisticated investor whose interests align with share appreciation. However, the heavy use of notes foreshadows dilution once the blocker lapses or if the base increases. Investors should track any future 13D moves that could indicate an activist tilt.

TL;DR � Passive filing limits immediate governance impact; monitor for 13D shift.

The Schedule 13G confirms Davidson Kempner is currently passive, mitigating control-change risk. Shared voting rights across entities concentrate influence in Yoseloff, but the 9.9 % cap prevents majority leverage. Should the fund re-file on Schedule 13D, governance dynamics could change rapidly, especially in light of convertible note triggers.

Le affiliate di Davidson Kempner comunicano una partecipazione passiva quasi massima del 9,9% in Biora Therapeutics (BIOR). Il 30 giugno 2025 il gruppo hedge fund � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP e il membro gestore Anthony A. Yoseloff � ha presentato l'emendamento n. 1 al Schedule 13G.

  • Proprietà effettiva totale: fino a 906.227 azioni ordinarie (inclusi 851.177 azioni convertibili da note), pari al 9,90% delle 4.552.702 azioni in circolazione di BIOR.
  • Struttura: Tutti i poteri di voto e dispositivi sono condivisi; nessuna entità ha potere esclusivo.
  • Note convertibili: Il 91% della posizione dichiarata è rappresentato da note convertibili in azioni, ma le conversioni sono limitate da un blocco al 9,90%, riducendo la diluizione immediata.
  • M.H. Davidson & Co. segnala separatamente 25.624 azioni (0,56%), incluse 24.033 da note.
  • Il gruppo certifica che la posizione è passiva (Regola 13d-1(c)) e non ha l’intenzione di influenzare il controllo.

La comunicazione evidenzia una significativa scommessa istituzionale su BIOR, mettendo in luce la possibile diluizione derivante dalle azioni convertibili, anche se il blocco limita l’espansione della proprietà nel breve termine.

Las filiales de Davidson Kempner revelan una participación pasiva cercana al máximo del 9,9% en Biora Therapeutics (BIOR). El 30 de junio de 2025, el grupo de fondos de cobertura � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP y el miembro gerente Anthony A. Yoseloff � presentó la Enmienda N° 1 al Schedule 13G.

  • Propiedad beneficiosa total: hasta 906,227 acciones comunes (incluyendo 851,177 acciones emitibles por conversión de notas), que representan el 9,90% de las 4,552,702 acciones en circulación de BIOR.
  • Estructura: Todo el poder de voto y disposición es compartido; ninguna entidad tiene poder exclusivo.
  • Notas convertibles: El 91% de la posición reportada está en notas convertibles en acciones, pero las conversiones están limitadas por un tope del 9,90%, lo que restringe la dilución inmediata.
  • M.H. Davidson & Co. reporta por separado 25,624 acciones (0,56%), incluyendo 24,033 provenientes de notas.
  • El grupo certifica que la posición es pasiva (Regla 13d-1(c)) y no pretende influir en el control.

La divulgación señala una apuesta institucional considerable en BIOR, destacando la posible dilución por valores convertibles, aunque el tope modera la expansión de la propiedad a corto plazo.

ë°ì´ë¹„드ìŠ� ì¼í”„ë„� 계열사가 Biora Therapeutics(BIOR)ì—� 대í•� ê±°ì˜ ìµœëŒ€ì¹˜ì¸ 9.9%ì� ìˆ˜ë™ ì§€ë¶„ì„ ê³µì‹œí–ˆìŠµë‹ˆë‹¤. 2025ë…� 6ì›� 30ì�, 헤지펀ë“� 그룹ì� M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP ë°� 매니ì§� 멤버 Anthony A. Yoseloffê°€ Schedule 13G 수정ì•� 1호를 제출했습니다.

  • ì´� 실질 소유ê¶�: 최대 906,227ì£� 보통ì£�(노트 전환으로 발행 가능한 851,177ì£� í¬í•¨)ë¡� BIORì� ì´� 4,552,702ì£� ì¤� 9.90%ì—� 해당합니ë‹�.
  • 구조: 모든 ì˜ê²°ê¶� ë°� 처분 ê¶Œí•œì€ ê³µìœ ë˜ë©°, ì–´ëŠ ë²•ì¸ë� ë‹¨ë… ê¶Œí•œì� ê°–ê³  있지 않습니다.
  • 전환사채: ë³´ê³ ë� í¬ì§€ì…˜ì˜ 91%ê°€ 주ì‹ìœ¼ë¡œ 전환 가능한 노트ì—� 해당하지ë§�, ì „í™˜ì€ 9.90% 제한 장치ì—� ì˜í•´ 제한ë˜ì–´ 즉ê°ì ì¸ í¬ì„ 효과ë¥� 줄입니다.
  • M.H. Davidson & Co.ëŠ� 노트ì—서 24,033주를 í¬í•¨í•� 25,624ì£�(0.56%)ë¥� 별ë„ë¡� 보고합니ë‹�.
  • ê·¸ë£¹ì€ ì� í¬ì§€ì…˜ì´ 수ë™ì ìž„ì� 규칙 13d-1(c)ì—� ë”°ë¼ ì¸ì¦í•˜ë©°, 지배력 행사 ì˜ë„ê°€ ì—†ìŒì� 명확íž� 합니ë‹�.

ì´ë²ˆ 공시ëŠ� BIORì—� 대í•� ìƒë‹¹í•� 기관 íˆ¬ìž ë² íŒ…ì� 나타내며, 전환 ì¦ê¶Œìœ¼ë¡œ ì¸í•œ í¬ì„ 가능성ì� 강조하지ë§� 제한 장치가 단기ì ì¸ ì§€ë¶� 확대ë¥� 완화합니ë‹�.

Les filiales de Davidson Kempner révèlent une participation passive proche du maximum de 9,9 % dans Biora Therapeutics (BIOR). Le 30 juin 2025, le groupe de hedge funds � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP et le membre gérant Anthony A. Yoseloff � a déposé l’Amendement n° 1 au Schedule 13G.

  • Propriété bénéficiaire totale : jusqu’Ã� 906 227 actions ordinaires (dont 851 177 actions pouvant être émises par conversion de billets), représentant 9,90 % des 4 552 702 actions en circulation de BIOR.
  • Structure : Tous les pouvoirs de vote et de disposition sont ±è²¹°ù³Ù²¹²µÃ©²õ ; aucune entité ne détient de pouvoir exclusif.
  • Billets convertibles : 91 % de la position déclarée est constituée de billets convertibles en actions, mais les conversions sont limitées par un plafond de 9,90 %, ce qui limite la dilution immédiate.
  • M.H. Davidson & Co. déclare séparément 25 624 actions (0,56 %), dont 24 033 provenant de billets.
  • Le groupe certifie que la position est passive (Règle 13d-1(c)) et n’a pas l’intention d’influencer le contrôle.

Cette divulgation signale un pari institutionnel important sur BIOR tout en soulignant la dilution potentielle liée aux titres convertibles, bien que le plafond limite l’expansion de la participation à court terme.

Davidson Kempner-Tochtergesellschaften geben eine nahezu maximale passive Beteiligung von 9,9 % an Biora Therapeutics (BIOR) bekannt. Am 30. Juni 2025 reichte der Hedgefonds-Komplex � M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP sowie Managing Member Anthony A. Yoseloff � Änderung Nr. 1 zum Schedule 13G ein.

  • Gesamtnutzungsrechte: Bis zu 906.227 Stammaktien (einschließlich 851.177 aus der Wandlung von Schuldscheinen), was 9,90 % der 4.552.702 ausstehenden BIOR-Aktien entspricht.
  • Struktur: Alle Stimm- und Verfügungsrechte werden geteilt; keine der Einheiten verfügt über Alleinrechte.
  • Wandelanleihen: 91 % der gemeldeten Position bestehen aus in Aktien wandelbaren Schuldscheinen, jedoch sind Wandlungen durch eine 9,90 %-Blockade begrenzt, wodurch eine sofortige Verwässerung eingeschränkt wird.
  • M.H. Davidson & Co. meldet separat 25.624 Aktien (0,56 %), davon 24.033 aus Wandelanleihen.
  • Die Gruppe bestätigt, dass die Position passiv ist (Regel 13d-1(c)) und nicht darauf abzielt, Kontrolle auszuüben.

Die Meldung signalisiert eine bedeutende institutionelle Wette auf BIOR und weist auf mögliche Verwässerungen durch wandelbare Wertpapiere hin, wobei die Blockade eine kurzfristige Ausweitung der Beteiligung begrenzt.

false 0001805284 0001805284 2025-08-04 2025-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported) August 4, 2025

 

Rocket Companies, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware 001-39432 84-4946470
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

1050 Woodward Avenue

Detroit, MI 48226

(Address of principal executive offices) (Zip Code)
 
(313) 373-7990
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Class A common stock, par value $0.00001 per share   RKT   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

Item 8.01 Other Events.

 

Tender Offers and Consent Solicitations

On August 4, 2025, Rocket Companies, Inc. (the “Company”), issued a press release announcing that the Company has commenced cash tender offers to purchase for cash any and all of Nationstar Mortgage Holdings Inc.’s (“Nationstar”) $650.0 million aggregate principal amount of outstanding 5.125% Senior Notes due 2030 (the “2030 Notes”) and any and all of Nationstar’s $600.0 million aggregate principal amount of outstanding 5.750% Senior Notes due 2031 (the “2031 Notes”) and a solicitation of consents to amend certain provisions of the indentures governing the 2030 Notes and 2031 Notes (the “Tender Offer Proposed Amendments”) to (i) eliminate the requirement to make a “Change of Control” offer for the related 2030 Notes and 2031 Notes following the consummation of the Company’s acquisition of Mr. Cooper Group Inc. (“Mr. Cooper”) and future transactions, (ii) eliminate substantially all of the restrictive covenants in the applicable Indenture and the 2030 Notes and 2031 Notes, (iii) eliminate certain conditions to legal defeasance or covenant defeasance in the applicable Indenture and the 2030 Notes and 2031 Notes and (iv) eliminate all events of default other than events of default relating to the failure to pay principal of and interest on the 2030 Notes and 2031 Notes (collectively, the “Tender Offers”). The terms and conditions of the Tender Offers are described in the Company’s Offer to Purchase and Consent Solicitation Statement, dated August 4, 2025 (the “Offer to Purchase”).

 

Exchange Offers and Consent Solicitations

Concurrently with the Tender Offers, the Company also issued a press release announcing that the Company has commenced an offer to exchange any and all of Nationstar’s $750.0 million aggregate principal amount of outstanding 6.500% Senior Notes due 2029 (the “2029 Notes”) and any and all of Nationstar’s $1.0 billion aggregate principal amount of outstanding 7.125% Senior Notes due 2032 (the “2032 Notes” and, together with the 2029 Notes, 2030 Notes, and 2031 Notes, the “Notes”) for up to $1.75 billion aggregate principal amount of new senior notes issued by the Company and a solicitation of consents to amend certain provisions of the indentures governing the 2029 Notes and 2032 Notes to (i) eliminate the requirement to make a “Change of Control” offer for the related 2029 Notes and 2032 Notes following the consummation of the Company’s acquisition of Mr. Cooper and future transactions, (ii) eliminate substantially all of the restrictive covenants in the applicable Indenture and the 2029 Notes and 2032 Notes, (iii) eliminate certain conditions to legal defeasance or covenant defeasance in the applicable Indenture and the 2029 Notes and 2032 Notes and (iv) eliminate all events of default other than events of default relating to the failure to pay principal of and interest on the 2029 Notes and 2032 Notes. (the “Exchange Offer Proposed Amendments” and, together with the Tender Offer Proposed Amendments, the “Proposed Amendments”) (collectively, the “Exchange Offers”). The terms and conditions of the Exchange Offers are described in the Company’s Offering Memorandum and Consent Solicitation Statement, dated August 4, 2025 (the “Offering Memorandum”).

 

The consummation of the Tender Offers and the Exchange Offers for the Notes of any series are subject to, and conditioned upon, the satisfaction or waiver of certain conditions described in the Offer to Purchase and Offering Memorandum, including, among other things, (a) the receipt of the Requisite Consents for such series of Notes, the execution by Nationstar and the applicable Trustee of the Supplemental Indenture for such series of Notes implementing the Proposed Amendments to the applicable Indenture and such Supplemental Indenture remaining a valid and binding agreement in full force and effect and (b) the substantially concurrent consummation of the acquisition of Mr. Cooper on terms and conditions set forth in the Agreement and Plan of Merger, dated as of March 31, 2025 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Maverick Merger Sub, Inc., Maverick Merger Sub 2, LLC, and Mr. Cooper.

A copy of the press releases relating to the Tender Offers and the Exchange Offers are attached hereto as Exhibit 99.1 and 99.2, respectively, and are incorporated by reference into this Item 8.01.

Forward Looking Statements

This communication contains statements herein regarding the proposed transaction between Rocket and Mr. Cooper. Future financial and operating results; benefits and synergies of the transaction; future opportunities for the combined company; the conversion of equity interests contemplated by the Agreement and Plan of Merger (the “Merger Agreement”) entered into by Rocket and Mr. Cooper on March 31, 2025; the issuance of common stock of Rocket contemplated by the Merger Agreement; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions and any other statements about future expectations that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements in this communication, other than statements of historical fact, are forward-looking statements that may be identified by the use of words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. Such forward-looking statements are based upon current beliefs, expectations and discussions related to the proposed transaction and are subject to significant risks and uncertainties that could cause actual results to differ materially from the results expressed in such statements.

 

 

 

Risks and uncertainties include, among other things, (i) the risk that the proposed transaction may not be completed in a timely basis or at all, which may adversely affect Rocket’s and Mr. Cooper’s businesses and the price of their respective securities; (ii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including stockholder approval by Mr. Cooper’s stockholders, and the potential failure to satisfy the other conditions to the consummation of the proposed transaction; (iii) the effect of the announcement, pendency or completion of the proposed transaction on each of Rocket’s or Mr. Cooper’s ability to attract, motivate, retain and hire key personnel and maintain relationships with others with whom Rocket or Mr. Cooper does business, or on Rocket’s or Mr. Cooper’s operating results and business generally; (iv) that the proposed transaction may divert management’s attention from each of Rocket’s and Mr. Cooper’s ongoing business operations; (v) the risk of any legal proceedings related to the proposed transaction or otherwise, including the risk of stockholder litigation in connection with the proposed transaction, or the impact of the proposed transaction thereupon, including resulting expense or delay; (vi) that Rocket or Mr. Cooper may be adversely affected by other economic, business and/or competitive factors; (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances which would require payment of a termination fee; (viii) the risk that restrictions during the pendency of the proposed transaction may impact Rocket’s or Mr. Cooper’s ability to pursue certain business opportunities or strategic transactions; (ix) the anticipated tax treatment of the proposed transaction may not be obtained, risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (x) the risk that the anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected; (xi) the impact of legislative, regulatory, economic, competitive and technological changes; (xii) risks relating to the value of Rocket securities to be issued in the proposed transaction; (xiii) the risk that integration of the Rocket and Mr. Cooper businesses post-closing may not occur as anticipated or the combined company may not be able to achieve the anticipated synergies expected from the proposed transaction, and the costs associated with such integration; and (xiv) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Rocket and Mr. Cooper.

These risks, as well as other risks related to the proposed transaction, are more fully described in a registration statement on Form S-4/A (the “Registration Statement”) filed by Rocket with the Securities and Exchange Commission (the “SEC”) on July 25, 2025 in connection with the proposed transaction. While the list of factors presented here and the list of factors presented in the Registration Statement are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Additional factors that may affect future results are contained in each company’s filings with the SEC, including each company’s most recent Annual Report on Form 10-K and Form 10-K/A, as it may be updated from time to time by quarterly reports on Form 10-Q and current reports on Form 8-K, all of which are available at the SEC’s website http://www.sec.gov. The information set forth herein speaks only as of the date hereof, and any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof is hereby disclaimed.

Item 9.01Financial Statements and Exhibits.
(d)Exhibits

 

Exhibit No.

 

Description

99.1   Press release, dated August 4, 2025, announcing the Tender Offers
     
99.2   Press release, dated August 4, 2025, announcing the Exchange Offers
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 4, 2025

 

  ROCKET COMPANIES, INC.  
       
 

By:

/s/ Noah Edwards  
  Name: Noah Edwards  
  Title: Chief Accounting Officer  

 

 

 

 

 

 

 

 

 

 

FAQ

How much of Biora Therapeutics (BIOR) does Davidson Kempner own?

The group reports beneficial ownership of up to 906,227 shares, or 9.90 % of outstanding common stock.

What is the composition of the reported BIOR stake?

Approximately 91 % of the position comes from notes convertible into common shares; the remainder is currently outstanding stock.

Does the filing indicate activist intent toward BIOR?

No. The Schedule 13G filing and certification state the securities are held for passive investment purposes.

What is the 9.90 % blocker mentioned in the filing?

The notes prohibit conversion that would push the group’s ownership above 9.90 %, limiting immediate voting power and dilution.

Could the convertible notes dilute existing BIOR shareholders?

Yes. If and when the blocker is lifted or the share count rises, 851,177 additional shares could enter the market.
Rocket Companies Inc

NYSE:RKT

RKT Rankings

RKT Latest News

RKT Latest SEC Filings

RKT Stock Data

34.81B
1.84B
1.36%
65.36%
3.86%
Mortgage Finance
Mortgage Bankers & Loan Correspondents
United States
DETROIT